Celularity Inc. CELU
At closeNov 3, 2026, 4:02 PM EST
After hours · Nov 3, 4:02 PM ET
- YTD
- -26.39%
- 1 year
- -52.49%
- Market cap
- 26.51M
- Revenue (ttm)
- 42.69M
- Profit margin
- -264.30%
- EPS (ttm)
- -1.69
- Shares out
- 22.48M
- Forward P/E
- -4.00
- YTD return
- -26.39%
- 1-year return
- -52.49%
- Volume
- 69.33K
- Avg volume
- 3.92M
- Open
- 0.8078
- Previous close
- 0.7914
- Day's range
- 0.799 – 0.8999
- 52-week range
- 0.56 – 2.55
- Beta
- 0.51
- Earnings date
- Oct 16, 2024
3M +0.1215 (+17.28%)
Key statistics
- Enterprise value
- 117.89M
- PEG ratio
- 0.00
- Price / sales
- 1.20
- Price / book
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 312.20%
- Free cash flow
- -33.17M
- Total cash
- 467.00K
- Total debt
- 67.36M
- Return on equity
- -154.23%
- Short % of float
- 25.13%
- 50-day average
- 2.38
- 200-day average
- 3.15
Next earnings
Oct 16, 2024
Expected Oct 16, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 6, 2024 | Sep 1, 2024 | 0.00 | -0.73 | — | — |
| Nov 7, 2024 | Jun 1, 2024 | 0.00 | -0.30 | — | — |
| Oct 16, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 2, 2024 | Sep 1, 2023 | 0.00 | -0.60 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.30 | 3.40 | +3.70 | +1,233.33% |
About Celularity Inc.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celularity.com
News
Celularity Enters Manufacturing Agreement With Vesalius For Its Peptual-Branded Peptide Active Pharmaceutical Ingredients 
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States 
Celularity Regains Nasdaq Compliance 
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement 
Stock Market: Will S&P 500 Open Up or Down Today? 
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner 
Celularity Q1 EPS $0.02 Up From $(0.84) YoY, Sales $3.846M Down From $11.426M YoY 
Celularity Announces Naveen Jain to Join Board of Directors - Celularity Announces Initial Closing Generating Over $10M In Gross Cash Proceeds From Private Placement Of Senior Secured Convertible Notes And Warrants
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Your note
Sign in to keep a note on CELU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DIAMANDIS PETER | Director | Stock Award(Grant) | Jun 13, 2023 | 1,307,070 |
| HARIRI ROBERT J | Chief Executive Officer | Purchase | Oct 4, 2023 | 28,570,400 |
| KEHLER DEAN C | Director | Stock Award(Grant) | Jun 13, 2023 | 236,066 |
| KILCOYNE ADRIAN | Officer | Stock Award(Grant) | Jul 13, 2023 | 1,175,000 |
| LIM KOK THAY | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 11, 2024 | 0 |
| MAZUR MARC B | Director | Stock Award(Grant) | Jun 13, 2023 | 236,066 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.22% | 500,132 | 1.14M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.61% | 137,474 | 313.44K | Sep 29, 2024 |
| Blackrock Inc. | 0.46% | 103,332 | 235.60K | Sep 29, 2024 |
| HB Wealth Management, LLC | 0.16% | 35,840 | 81.72K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.16% | 35,000 | 79.80K | Sep 29, 2024 |
| Northern Trust Corporation | 0.15% | 34,062 | 77.66K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.50% | 337,262 | 768.96K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.69% | 155,085 | 353.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.31% | 70,407 | 160.53K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.10% | 22,822 | 52.03K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 20,859 | 47.56K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 15,984 | 36.44K | Oct 30, 2024 |